{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:13:35Z","timestamp":1790874815987,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH Fogarty International Center, NINDS, NIMH, NHBLI and NIEHS","award":["NIH Research Training Grant # D43 TW009340"],"award-info":[{"award-number":["NIH Research Training Grant # D43 TW009340"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the preferred first-line treatment for persons living with HIV (PLHIV) including children and adolescents in many low- and middle-income countries including Uganda. However, there are concerns about excessive weight gain associated with DTG especially in adults. There remains paucity of current information on weight-related outcomes among adolescents on DTG. We determined the prevalence of excessive weight gain and associated factors among adolescents living with HIV (ALHIV) receiving DTG-based ART in Kampala, Uganda.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cross-sectional study involving ALHIV aged 10\u201319 years on DTG-based ART for at least one year were recruited from public health facilities in Kampala between February and May 2022. Excessive weight gain was defined as becoming overweight or obese per body mass index (BMI) norms while on DTG-based ART for at least one year. Demographic, clinical and laboratory data were collected using interviewer-administered questionnaires and data extracted from medical records. At enrolment, blood pressure and anthropometry were measured and blood was drawn for blood glucose and lipid profile. Data was summarised using descriptive statistics and logistic regression was performed to determine the associated factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 165 ALHIV with a median age of 14 years (IQR 12\u201316). Eighty (48.5%) were female. The median duration on ART and DTG was 8 years (IQR 7\u201311) and 2 years (IQR 1\u20133) respectively. At DTG initiation, the majority of participants (152\/165, 92.1%) were ART-experienced, and had normal BMI (160\/165, 97%). Overall, 12\/165 (7.3%) adolescents (95% CI: 4.2\u201312.4) had excessive weight gain. No factors were significantly associated with excessive weight gain after DTG start in ALHIV. However, all ALHIV with excessive weight gain were females.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study found a prevalence of 7.3% of overweight and obesity in ALHIV after initiating DTG. We did not find any factor significantly associated with excessive weight gain in ALHIV on DTG. Nonetheless, we recommend ongoing routine monitoring of anthropometry and metabolic markers in ALHIV as DTG use increases globally, to determine the exact magnitude of excessive weight gain and to identify those at risk of becoming overweight or obese while taking the medication.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-024-00615-6","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:01:58Z","timestamp":1713441718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda"],"prefix":"10.1186","volume":"21","author":[{"given":"Irene","family":"Nakatudde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Katana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Laker","family":"Agnes Odongpiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Alice","family":"Nalugga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Glenn","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Musoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"615_CR1","volume-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019."},{"issue":"7","key":"615_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11908-020-00727-w","volume":"22","author":"SE P\u00e9rez","year":"2020","unstructured":"P\u00e9rez SE, Chow SP, Kania A, Goldberg R, Badowski ME. Weighing in on the role of integrase strand transfer inhibitors (INSTIs) on Weight Gain: fact or fiction? Curr Infect Dis Rep. 2020;22(7):19.","journal-title":"Curr Infect Dis Rep"},{"issue":"7","key":"615_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2019","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater Weight Gain in treatment-naive persons starting Dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019;70(7):1267\u201374.","journal-title":"Clin Infect Dis"},{"key":"615_CR4","doi-asserted-by":"crossref","unstructured":"Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN et al. Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. 2020;23(4):e25484.","DOI":"10.1002\/jia2.25484"},{"issue":"9","key":"615_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"615_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"The NAMSAL ANRS 12313 Study Group","year":"2019","unstructured":"The NAMSAL ANRS 12313 Study Group. Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326.","journal-title":"N Engl J Med"},{"key":"615_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2055-6640(20)30277-6","volume":"5","author":"A Hill","year":"2019","unstructured":"Hill A, Waters L, Pozniak A. Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Eradication. 2019;5:41\u20133.","journal-title":"J Virus Eradication"},{"issue":"5","key":"615_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/QAI.0000000000003087","volume":"91","author":"K Bourgi","year":"2022","unstructured":"Bourgi K, Ofner S, Musick B, Griffith B, Diero L, Wools-Kaloustian K, et al. Weight gain among Treatment-Na\u00efve persons with HIV receiving Dolutegravir in Kenya. J Acquir Immune Defic Syndr. 2022;91(5):490\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"615_CR9","doi-asserted-by":"crossref","unstructured":"Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and Tenofovir Alafenamide: what is the mechanism and does it Matter? Open Forum Infect Dis. 2021;8(12).","DOI":"10.1093\/ofid\/ofab542"},{"key":"615_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fendo.2018.00705","volume":"9","author":"S Kumar","year":"2018","unstructured":"Kumar S, Samaras K. The impact of Weight Gain during HIV Treatment on Risk of pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018;9:705.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"615_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/hiv.12294","volume":"17","author":"AC Achhra","year":"2016","unstructured":"Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016;17(4):255\u201368.","journal-title":"HIV Med"},{"key":"615_CR12","doi-asserted-by":"crossref","unstructured":"Herrin M, Tate JP, Akg\u00fcn KM, Butt AA, Crothers K, Freiberg MS et al. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. Journal of acquired immune deficiency syndromes (1999). 2016;73(2):228\u2009\u2013\u200936.","DOI":"10.1097\/QAI.0000000000001071"},{"key":"615_CR13","doi-asserted-by":"crossref","unstructured":"Taramasso L, Bonfanti P, Ricci E, Orofino G, Squillace N, Menzaghi B et al. Factors Associated with Weight Gain in people treated with Dolutegravir. Open Forum Infect Dis. 2020;7(6).","DOI":"10.1093\/ofid\/ofaa195"},{"issue":"6","key":"615_CR14","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight Gain following initiation of antiretroviral therapy: risk factors in Randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"615_CR15","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk factors for Weight Gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2020;71(9):e471\u20137.","journal-title":"Clin Infect Diseases: Official Publication Infect Dis Soc Am"},{"issue":"11","key":"615_CR16","doi-asserted-by":"publisher","first-page":"e25970","DOI":"10.1002\/jia2.25970","volume":"25","author":"CL Townsend","year":"2022","unstructured":"Townsend CL, O\u2019Rourke J, Milanzi E, Collins IJ, Judd A, Castro H, et al. Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review. J Int AIDS Soc. 2022;25(11):e25970.","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"615_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/INF.0000000000003878","volume":"42","author":"JM Bacha","year":"2023","unstructured":"Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J, et al. Realizing the Promise of Dolutegravir in effectively treating children and adolescents living with HIV in Real-world settings in 6 countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023;42(7):576\u201381.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"615_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12887-022-03292-4","volume":"22","author":"EC Kip","year":"2022","unstructured":"Kip EC, Udedi M, Kulisewa K, Go VF, Gaynes BN. Stigma and mental health challenges among adolescents living with HIV in selected adolescent-specific antiretroviral therapy clinics in Zomba District, Malawi. BMC Pediatr. 2022;22(1):253.","journal-title":"BMC Pediatr"},{"issue":"1","key":"615_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12879-023-08174-3","volume":"23","author":"G Guaraldi","year":"2023","unstructured":"Guaraldi G, Bonfanti P, Di Biagio A, Gori A, Mili\u0107 J, Saltini P, et al. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda. BMC Infect Dis. 2023;23(1):230.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"615_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ofid\/ofab308","volume":"8","author":"WLA Koay","year":"2021","unstructured":"Koay WLA, Dirajlal-Fargo S, Levy ME, Kulie P, Monroe A, Castel AD, et al. Integrase strand transfer inhibitors and Weight Gain in Children and Youth with Perinatal Human Immunodeficiency Virus in the DC Cohort. Open Forum Infect Dis. 2021;8(7):308.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"615_CR21","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/cid\/ciaa1652","volume":"73","author":"N Thivalapill","year":"2021","unstructured":"Thivalapill N, Simelane T, Mthethwa N, Dlamini S, Lukhele B, Okello V, et al. Transition to Dolutegravir is Associated with an increase in the rate of body Mass Index Change in a cohort of virally suppressed adolescents. Clin Infect Dis. 2021;73(3):e580\u20136.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"615_CR22","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1097\/INF.0000000000003076","volume":"40","author":"DK Yeoh","year":"2021","unstructured":"Yeoh DK, Campbell AJ, Bowen AC. Increase in body Mass Index in Children with HIV, switched to Tenofovir Alafenamide Fumarate or Dolutegravir containing antiretroviral regimens. Pediatr Infect Dis J. 2021;40(5):e215\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"615_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/microorganisms8060864","volume":"8","author":"L Taramasso","year":"2020","unstructured":"Taramasso L, Di Biagio A, Bovis F, Forlanini F, Albani E, Papaioannu R, et al. Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-Infected young adults and adolescents: a 10-Year observational study. Microorganisms. 2020;8(6):864.","journal-title":"Microorganisms"},{"key":"615_CR24","unstructured":"Turkova A, Kityo C, Mujuru HA, Variava E, Kekitiinwa A, Lugemwa A et al. Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial. The 11th IAS Conference on HIV Science; 18\u201321 July 2021; Berlin, Germany: International AIDS Society; 2021."},{"issue":"9","key":"615_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/hiv.13302","volume":"23","author":"P Frange","year":"2022","unstructured":"Frange P, Avettand-Fenoel V, Veber F, Blanche S. No overall impact on body mass index for age change after dolutegravir initiation in a French paediatric cohort. HIV Med. 2022;23(9):1019\u201324.","journal-title":"HIV Med"},{"issue":"5","key":"615_CR26","doi-asserted-by":"publisher","first-page":"e0232419","DOI":"10.1371\/journal.pone.0232419","volume":"15","author":"VM Nabitaka","year":"2020","unstructured":"Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study. PLoS ONE. 2020;15(5):e0232419.","journal-title":"PLoS ONE"},{"key":"615_CR27","unstructured":"Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. February 2020."},{"issue":"3","key":"615_CR28","doi-asserted-by":"publisher","first-page":"e0230707","DOI":"10.1371\/journal.pone.0230707","volume":"15","author":"L Aurpibul","year":"2020","unstructured":"Aurpibul L, Namwongprom S, Sudjaritruk T, Ounjaijean S. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment. PLoS ONE. 2020;15(3):e0230707.","journal-title":"PLoS ONE"},{"key":"615_CR29","first-page":"9241208546","volume-title":"Physical status: the Use and Interpretation of Anthropometry - Report of a WHO Expert Committee","author":"World Health Organization","year":"1995","unstructured":"World Health Organization. Physical status: the Use and Interpretation of Anthropometry - Report of a WHO Expert Committee. Geneva: World Health Organization; 1995. p. 9241208546."},{"key":"615_CR30","unstructured":"World Health Organization. Growth reference data for 5\u201319 years: World Health Organization. 2007 [Accessed 29 January 2021]. http:\/\/www.who.int\/toolkits\/growth-reference-data-for-5to19-years."},{"key":"615_CR31","doi-asserted-by":"crossref","unstructured":"Di Bonito P, Di Sessa A. New Diagnostic Criteria for Hypertension in Children and adolescents. Lights Shadows. 2020;7(11).","DOI":"10.3390\/children7110196"},{"key":"615_CR32","unstructured":"World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO\/IDF consultation. Geneva, Switzeland: 2006."},{"issue":"Suppl 1","key":"615_CR33","first-page":"S81","volume":"37","author":"Diagnosis and classification of diabetes mellitus","year":"2014","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81\u201390.","journal-title":"Diabetes Care"},{"issue":"3","key":"615_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1542\/peds.89.3.495","volume":"89","author":"NCEP Expert Panel on Blood Cholesterol Levels in Children Adolescents. National Cholesterol Education Program (NCEP)","year":"1992","unstructured":"NCEP Expert Panel on Blood Cholesterol Levels in Children Adolescents. National Cholesterol Education Program (NCEP). Highlights of the report of the Expert Panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89(3):495\u2013501.","journal-title":"Pediatrics"},{"key":"615_CR35","unstructured":"World Health Organization. Anthro\u00ae plus version 1.0.2. 2010 [Accessed 29 January 2021]. http:\/\/www.who.int\/growthref."},{"key":"615_CR36","doi-asserted-by":"crossref","unstructured":"Namara D, Schwartz JI, Tusubira AK, McFarland W. The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study. 2022;33(14):1158\u201364.","DOI":"10.1177\/09564624221129410"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00615-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00615-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:03:18Z","timestamp":1713441798000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00615-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00615-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"26 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Infectious Diseases Institute Research Ethics Committee REF# 023\/2021 and the Uganda National Council for Science and Technology Ref: HS1837ES. In addition, administrative clearance was obtained from the KCCA Directorate of Public Health & Environment, Ref: DPHE\/KCCA\/1301. Written informed consent was obtained from adolescents who were 18 years and older and emancipated minors. Written assent was obtained from adolescents aged 10\u201317 years who were not emancipated minors, after obtaining written informed consent from the parent or caretaker.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}